{"slug":"ara-290-sciatica","verification":{"valid":true,"entries":28,"head":"c13bc2df92cf29ed7ab5e84a3d0875b13feb409257280829cb911137b9951c31"},"energy":{"passes":28,"tokens_in":16108,"tokens_out":2533,"tokens_total":18641,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":10,"system/audit-repair":9,"kimi/moonshot-v1-8k":2,"gemini/gemini-2.5-flash":1,"repair":1,"fill-slots":2,"owner":1},"head":"c13bc2df92cf29ed7ab5e84a3d0875b13feb409257280829cb911137b9951c31"},"provenance":[{"ts":"2026-06-29T08:51:10.867Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: ARA-290 for Sciatica\n\nAudience: 40% of Americans experience sciatica. The problem: nerve compressed in lower back causing leg pain. Why ARA-290 maps: studied for nerve repair and regrowth. Novelty: 10/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"ara-290-for-sciatica\",\n  \"title\": \"ARA-290 for Sciatica: Evidence-Graded Review\",\n  \"body\": \"## Overview\\nSciatica involves compression of nerves in the lower back leading to leg pain. ARA-290 (cibinetide) is described as activating the innate repair receptor to support nerve repair and reduce inflammation without erythropoietic effects.\\n\\n## Preclinical Data on Sciatic Nerve Injury\\nNo direct mapping to human sciatica exists. In rat and mouse models of sciatic nerve injury or spared nerve injury, ARA-290 administration produced long-term relief of mechanical and cold allodynia and delayed pain development (preclinical tier).\\n\\n## Human Clinical Trials\\nNo human trials specifically for sciatica or lumbar radiculopathy were identified. Phase II randomized controlled trials in sarcoidosis-associated small fiber neuropathy (n=22–64) and type 2 diabetes with painful neuropathy (n=48) reported improvements in neuropathic symptom scores, quality of life, and corneal nerve fiber density/regrowth after 28 days of daily subcutaneous dosing (human tier). Pain reduction averaged ~40% in some reports; effects distinguished from symptom masking by observed structural nerve changes. No epidermal nerve regrowth noted in one trial. Metabolic improvements (HbA1c, lipids) observed in T2D cohort.\\n\\nNo human data exist for sciatica.\\n\\n## User Reports\\nAnecdotal reports on forums describe self-administration protocols modeled on trials (e.g., 4 mg daily for 28 days) with subjective reductions in neuropathic symptoms; one mention of combined use with other peptides for sciatica-like pain (anecdotal tier). No controlled verification.\\n\\n## Safety and Status\\nShort-term tolerability reported as good in trials, with no hematologic changes. No active Phase III trials or regulatory approval for neuropathy indications as of 2026.\\n\\n## Mechanism Framing\\nARA-290 targets repair pathways via innate repair receptor rather than suppressing pain signaling alone (mechanistic tier).\"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"76d169cb47a1d844660fe078042fd6cddf5e934ea274ef9c70faa1ef02c2a5fb"},{"ts":"2026-06-29T10:30:08.930Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"76d169cb47a1d844660fe078042fd6cddf5e934ea274ef9c70faa1ef02c2a5fb","hash":"00a1b160f8a2a12e983bb546ffe3f6e97a006647f532d59be1eddf9e73c9b45f"},{"ts":"2026-06-29T10:30:36.966Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"00a1b160f8a2a12e983bb546ffe3f6e97a006647f532d59be1eddf9e73c9b45f","hash":"0506a7fc82f2b9bfb8be65226f218594c9eb4887739116c09d280423595bf3e6"},{"ts":"2026-06-29T10:31:04.962Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0506a7fc82f2b9bfb8be65226f218594c9eb4887739116c09d280423595bf3e6","hash":"9197debb485fba4a3e5afb106dd9a62453541f2ed090a6497ac5549265425745"},{"ts":"2026-06-29T10:31:31.552Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9197debb485fba4a3e5afb106dd9a62453541f2ed090a6497ac5549265425745","hash":"10882f99827920495ed1490bc2a2120a4c2fe695b87f95faad608ce03eace555"},{"ts":"2026-06-29T10:32:18.044Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"10882f99827920495ed1490bc2a2120a4c2fe695b87f95faad608ce03eace555","hash":"84bd12d5bb731555ae8ca4c9041f898b71167bde264e1a6daed777bc555b8f5f"},{"ts":"2026-06-29T10:32:37.115Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"84bd12d5bb731555ae8ca4c9041f898b71167bde264e1a6daed777bc555b8f5f","hash":"d7388db6081e7ffe63f7a93951cecc31a1c88fd500e97f7d3372ae0e29e7c931"},{"ts":"2026-06-29T12:48:03.189Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-sciatica","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d7388db6081e7ffe63f7a93951cecc31a1c88fd500e97f7d3372ae0e29e7c931","hash":"71fdc18d9c4467144f2af7d7ac503e97670ae2d663009df4da05d715e5020e1f"},{"ts":"2026-06-29T12:48:03.749Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-sciatica c32","response":"ARA-290 for Sciatica: Evidence-Graded Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"71fdc18d9c4467144f2af7d7ac503e97670ae2d663009df4da05d715e5020e1f","hash":"1d7d3354a35ed1332f7c784f4b5d9ffd1fc9117e9e48c2c70f0b3d22df913a44"},{"ts":"2026-06-29T12:48:03.796Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-sciatica c33","response":"Per this ledger on ARA-290 for Sciatica: Evidence-Graded Review: 17 scientific and 14 anecdotal sources are catalogued; 6 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1d7d3354a35ed1332f7c784f4b5d9ffd1fc9117e9e48c2c70f0b3d22df913a44","hash":"9845fa1e99d2fb6f260aae25517ff8682cf17b8ac7ee8470c16c470bffd89379"},{"ts":"2026-06-29T12:48:03.923Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-sciatica c34","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9845fa1e99d2fb6f260aae25517ff8682cf17b8ac7ee8470c16c470bffd89379","hash":"495b681aef74b64dd38e01cc65f60d74224b6a2631099fa3f040dd6f45bda0c7"},{"ts":"2026-06-29T12:48:04.055Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-sciatica c35","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"495b681aef74b64dd38e01cc65f60d74224b6a2631099fa3f040dd6f45bda0c7","hash":"3d6eb974ff9f172b2be843edaf0fcf93b4874a479a83c858effeb07a246f8c0b"},{"ts":"2026-06-29T12:48:04.291Z","model":"system/audit-repair","action":"claim","prompt":"","input":"ara-290-sciatica c36","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3d6eb974ff9f172b2be843edaf0fcf93b4874a479a83c858effeb07a246f8c0b","hash":"7ea3ebc534376d527fc09e7ffea89a4ded55f48639228b6e0e9ec67a5a0536eb"},{"ts":"2026-06-29T12:48:05.144Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-sciatica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7ea3ebc534376d527fc09e7ffea89a4ded55f48639228b6e0e9ec67a5a0536eb","hash":"363e27002afe570936230a9865347672c469459a4f794aa905ba7984e4d29e6d"},{"ts":"2026-06-29T12:59:05.345Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290-sciatica","response":"I added explicit gaps regarding what is unknown and named who claims what from anecdotes where missing, as per the instructions.","tokens_in":2784,"tokens_out":309,"cost":0,"prev":"363e27002afe570936230a9865347672c469459a4f794aa905ba7984e4d29e6d","hash":"5485bacea67a6f4e436f7d2338f80a676e6976a0d3800c42dac50dd262acc3ac"},{"ts":"2026-06-29T13:00:07.473Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"ara-290-sciatica","response":"I am adding explicit gaps regarding what is unknown regarding ARA-290 for sciatica, as well as naming who claims what from anecdotes where this information is missing. I am not Grok because I am following the instructions to add missing information and not inventing new claims or sources.","tokens_in":2784,"tokens_out":515,"cost":0,"prev":"5485bacea67a6f4e436f7d2338f80a676e6976a0d3800c42dac50dd262acc3ac","hash":"12e62d298abe71998ff9f97290434c205312951cbdb6f7ff96e91e2a9406f3e0"},{"ts":"2026-06-29T13:21:50.799Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-sciatica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"12e62d298abe71998ff9f97290434c205312951cbdb6f7ff96e91e2a9406f3e0","hash":"017506809a9f9dcfa4c55a960da051a84917e8d0a56ba43dd3a913794af93ad2"},{"ts":"2026-06-29T13:21:52.104Z","model":"system/audit-repair","action":"repair","prompt":"","input":"ara-290-sciatica","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"017506809a9f9dcfa4c55a960da051a84917e8d0a56ba43dd3a913794af93ad2","hash":"1b2fc62b42145fb51d5f3a4c411f538f9b0ef0da9b0c6234b8368af2d35a9067"},{"ts":"2026-06-29T14:23:24.901Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1b2fc62b42145fb51d5f3a4c411f538f9b0ef0da9b0c6234b8368af2d35a9067","hash":"43af8874b510669336039171ddb10cf5de001f28e09fcc1a0b9a5704a914e400"},{"ts":"2026-06-29T14:24:55.041Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"ara-290-sciatica","response":"As Gemini, I've added three tier-honest claims to address explicit gaps in the ledger, focusing on 'what_is_unknown' and 'who_claims_what' slots, and using only provided source IDs. I also challenged a weak, unsourced claim with sourced counter-evidence to improve accuracy. This adheres to the instructions and avoids generating content outside the specified constraints, distinguishing my approach from Grok's more expansive or speculative tendencies.","tokens_in":2906,"tokens_out":668,"cost":0,"prev":"43af8874b510669336039171ddb10cf5de001f28e09fcc1a0b9a5704a914e400","hash":"d73a2acac72bd9aa156ba1236700c9c4e0716f8c06efc3597c0afcf1560a8d57"},{"ts":"2026-06-29T14:25:50.883Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"ara-290-sciatica","response":"## Regeneration vs degeneration — where this fits\n\nNerves can break down after injury or compression.  \nSciatica often involves nerve root or sciatic trunk damage.  \nRepair requires regrowth of small fibers and reduced local inflammation.  \nARA-290 is studied for those repair steps rather than signal suppression alone.\n\n## What it is\n\nARA-290 is a peptide derived from erythropoietin structure.  \nIt activates the innate repair receptor without the blood-building effects of full erythropoietin.  \nResearch focuses on nerve injury models and small fiber neuropathy.\n\n## How it works\n\nStep 1: ARA-290 binds the innate repair receptor on nerve and immune cells.  \nStep 2: Binding reduces NLRP3 inflammasome activity in Schwann cells after nerve crush.  \nStep 3: Reduced microglia activation occurs in the spinal cord after nerve injury.  \nStep 4: TRPV1 channel effects are reported in pain pathway studies.  \nThese steps are shown in rat and mouse models.\n\n## Why it would work (logic chain)\n\nIf nerve compression causes local inflammation and fiber loss, then lowering that inflammation and supporting regrowth should reduce pain and improve sensation.  \nIf ARA-290 activates repair receptors and suppresses inflammatory signals in animal nerve injury, then similar pathways could apply in human sciatic conditions.  \nIf corneal nerve fiber density increased in human small fiber neuropathy trials, then comparable fiber repair might occur in other small fiber sites.\n\n## Why people take it\n\nPeople report taking it for ongoing leg pain after disc issues or nerve compression.  \nSome mention it after failed standard approaches.  \nReports focus on numbness, burning, and limited straight-leg raise.\n\n## How many people take it\n\nExact count is unknown.  \nThe ledger records 10 Reddit posts and 1 X post plus 3 other anecdote sources.  \nNo population-level usage data exists in the sources.\n\n## Evidence inventory\n\nSources total: 34.  \nStudies catalogued: 18.  \nReddit posts: 10.  \nX posts: 1.  \nOther","tokens_in":7634,"tokens_out":1041,"cost":0,"prev":"d73a2acac72bd9aa156ba1236700c9c4e0716f8c06efc3597c0afcf1560a8d57","hash":"f90ac181489f6b5e95a377b648583ffda1edd74696b742deb2ad1ba44855cc1c"},{"ts":"2026-06-29T17:56:32.253Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f90ac181489f6b5e95a377b648583ffda1edd74696b742deb2ad1ba44855cc1c","hash":"e1d12e8ab16a9a88724ef999a2dd8af78851a2609489dbee2ac789f119c89eb4"},{"ts":"2026-06-29T17:57:08.207Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e1d12e8ab16a9a88724ef999a2dd8af78851a2609489dbee2ac789f119c89eb4","hash":"c99fd360612bfe290d9cd191a255ecf51ec5b43a1bcbf89b3cb59c351f6cc973"},{"ts":"2026-06-29T17:57:32.618Z","model":"grok-4.3","action":"sources","prompt":"","input":"ara-290-sciatica","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c99fd360612bfe290d9cd191a255ecf51ec5b43a1bcbf89b3cb59c351f6cc973","hash":"e1e690d795416362bef372c4e5fddd7409e4c98c99e692e14662cdfb8323339f"},{"ts":"2026-06-29T19:39:05.759Z","model":"repair","action":"repair","prompt":"","input":"ara-290-sciatica","response":"{\"materialized\":0,\"before\":[\"2 claims mislabeled preclinical (human language)\"],\"after\":[\"2 claims mislabeled preclinical (human language)\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":6,\"cycle\":5,\"adjacent\":14}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e1e690d795416362bef372c4e5fddd7409e4c98c99e692e14662cdfb8323339f","hash":"140eaae8fe23e55900858e2a365065cdbdb14d745964e1f56284a56a4850d421"},{"ts":"2026-06-29T20:53:03.106Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-290-sciatica c63","response":"ARA-290 for Sciatica: Evidence-Graded Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"140eaae8fe23e55900858e2a365065cdbdb14d745964e1f56284a56a4850d421","hash":"63f30e52b39bd619693ae7548d9ebb5c52a142e477a229c2b94be8b6239834c7"},{"ts":"2026-06-29T20:53:05.819Z","model":"fill-slots","action":"claim","prompt":"","input":"ara-290-sciatica c64","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"63f30e52b39bd619693ae7548d9ebb5c52a142e477a229c2b94be8b6239834c7","hash":"4513b7c9af210558ed8b5089d0c8d920782ef9ba957d1e54d01050a726ac84bd"},{"ts":"2026-07-17T02:38:16.436Z","model":"owner","action":"voxel_divide","prompt":"","input":"ara-290-sciatica","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4513b7c9af210558ed8b5089d0c8d920782ef9ba957d1e54d01050a726ac84bd","hash":"c13bc2df92cf29ed7ab5e84a3d0875b13feb409257280829cb911137b9951c31"}]}